Published in Obesity and Diabetes Week, September 5th, 2005
The ODAC panel is a committee of external experts, formed by the U.S. Food and Drug Administration (FDA), to advise the FDA in the evaluation of marketed and investigational drugs for use in the treatment of cancer.
In July 2005, the FDA accepted for filing and review the supplemental new drug application (sNDA) for use of Tarceva plus gemcitabine chemotherapy for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week